景川
liked and commented on
$Emergent BioSolutions (EBS.US)$ Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Pre...
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Pre...
3
6
景川
liked
$NIO Inc (NIO.US)$ Isn't that supposed to be UP since a few months ago Without those funds manipulating it by PRESSING down till so low?
1
景川
liked
$OS Therapies (OSTX.US)$
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dos...
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dos...
2
景川
reacted to
$OS Therapies (OSTX.US)$
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer
Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer
Strong safety profile for FRA-H wit...
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer
Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer
Strong safety profile for FRA-H wit...
1
景川
liked
$Wolfspeed (WOLF.US)$ According to the above article. Wolfspeed Inc. WOLF ranks second on the list for expected sales CAGR through 2026.
1
景川
commented on
$Taiwan Semiconductor (TSM.US)$ TRASH CHINA STOCK WILL NEVER RECOVER
3
8
景川
liked
$XPeng (XPEV.US)$ NIO short squeeze! need some buyers! The price has been going up even though shorts are piling on. Very undervalued stock!
3
景川
liked
$Elevai Labs (ELAB.US)$ Never lend your stocks to short sellers because the loss they bring to you by short selling stocks will be greater than the interest they give you. It's like selling a gun to someone who wants to kill you, so don't lend them any money no matter how much they offer.
Translated
3
景川
liked
$Super Micro Computer (SMCI.US)$
Many people are often contradictory. When a company just goes public and issues shares, it will attract a swarm of people to rush to buy. When new shares are issued later, it will arouse suspicion. It should be noted that the purpose of issuing shares is for fundraising, and the reasons for fundraising may be that the company has new major projects or to repay loans. Issuing new shares requires approval from the Securities Commission, and during the process, a plan needs to be submitted. It takes time to prove the reliability of the plan, and this plan is issued only with the consent of the shareholders. The shareholders who approve this plan are the shareholders who hold shares in the company...
Many people are often contradictory. When a company just goes public and issues shares, it will attract a swarm of people to rush to buy. When new shares are issued later, it will arouse suspicion. It should be noted that the purpose of issuing shares is for fundraising, and the reasons for fundraising may be that the company has new major projects or to repay loans. Issuing new shares requires approval from the Securities Commission, and during the process, a plan needs to be submitted. It takes time to prove the reliability of the plan, and this plan is issued only with the consent of the shareholders. The shareholders who approve this plan are the shareholders who hold shares in the company...
Translated
3
景川
commented on
$NVIDIA (NVDA.US)$ plz dump everything you have in NVIDIA this will drop to 75-80 next week and plz put it in Gme and Amc they will make you rich next week
7
4
景川 : A HUGE + NEWS!
景川 Trytosaveabit OP : It can be seen that $Emergent BioSolutions (EBS.US)$ has been recognized and trusted by the U.S government!